简体中文
原料药
product| Name |
Chemical Name |
Cas No. |
Key Intermediates (Cas No.) |
Status |
Indication |
Purity or Assay |
| 沙格列汀 | Saxagliptin | 945667-22-1 | 361440-67-7 709031-45-8 | CFDA USFDA | Ⅱ型糖尿病 | 98.0%~102.0% |
| 枸橼酸托法替布 | Tofacitinib Citrate | 540737-29-9 | 3680-69-1 479633-63-1 | Lab completed | JAK通路抑制剂；类风湿性关节炎 | 98.0%~102.0% |
| 恩曲他滨 | Emtricitabine | 143491-57-0 | 147126-75-8 2022-85-7 147126-62-3 | USFDA WHO | HIV-1、乙肝 | ≥98.5% |
| 他扎罗汀 | Tazarotene | 118292-40-3 | NA | CFDA | 用于治疗银屑病、痤疮，并用于角化异常性疾病、毛囊皮脂腺疾病、皮肤癌前期病变 | 98.5%~101.5% |
| 替格瑞洛 | Ticagrelor | 274693-27-5 | 51336-95-9 376608-71-8 376608-65-0 | Lab completed | 用于急性冠脉综合征 | ≥99.0% |
| (8-[2-羟基苯甲酰基]-氨基)辛酸钠 | Salcaprozate Sodium | 203787-91-1 | NA | Developing | 口服吸收促进剂 | ≥99% |
| 雷诺嗪 | Ranolazine | 95635-55-5 | 2210-74-4; 1131-01-7; 5294-61-1; | Developing | 治疗慢性心绞痛药 | ≥99% |
| 甲磺酸达比加群酯 | Dabigatran Etexilate Mesylate; Pradaxa | 872728-81-9 | 212322-56-0 | Lab completed | 抗凝血药物 | 98.0%~102.0% |